1. Home
  2. Protocols and Guidelines
  3. Upcoming CAP Guidelines
  4. Evaluation of MRD Testing in ALL

Evaluation of MRD Testing in ALL

Background

The standard-of-care for monitoring treatment response in acute lymphoblastic leukemia (ALL) is measurable residual disease (MRD) testing. Several testing methodologies, including immunophenotypic (flow cytometric) and molecular (polymerase chain reaction and next-generation sequencing) assays, are currently utilized. Moreover, optimal treatment time points, sample types and quality, assay protocols, and interpretative strategies are not established. The goal of this guideline is to establish evidence-based standards and expert recommendations in the application, interpretation, and actionability of MRD for pediatric and adult B-cell ALL (B-ALL).

Scope

The primary goal of this guideline is to address clinical evaluation of MRD in ALL. The evidence-based recommendations will focus on optimal MRD testing methods.

Key Questions

1a. In patients with Philadelphia chromosome negative (Ph-) B-ALL, which method (flow cytometry or NGS) is best for evaluating MRD status at post-induction, post-consolidation, pretransplant, and posttransplant treatment timepoints?

1b. In patients with Philadelphia chromosome positive (Ph+) B-ALL, which method (PCR, flow cytometry, or NGS) is best for evaluating MRD status at post-induction, post-consolidation, pretransplant, and posttransplant treatment timepoints?

2. In patients with B-ALL, do peripheral blood specimens have concordance with bone marrow aspirates for detecting MRD?

3. For bone marrow aspirates from B-ALL patients, what are the optimum and minimum cellularity requirements for accurate assessment of MRD?

Guideline information

  • Guideline status: Research and Review

Expert Panel Members

  • Genevieve Crane, MD, PhD, FCAP, Co-chair
  • Alexandra Kovach, MD, FCAP, Co-chair
  • Daniel Boyer, MD, PhD, FCAP
  • Sindhu Cherian, MD, FCAP
  • Yi Ding, MD, FCAP
  • Mark Ewalt, MD, FCAP
  • Benjamin Hedley, PhD
  • Yen-Chun Liu, MD, PhD, FCAP
  • Lori Muffly, MD
  • Rachel Rau, MD
  • Julie Rosser, DO, FCAP
  • Julie Donovan, MLS(ASCP)
  • Lindsy Frazer-Green, PhD
  • Marisol Hernandez, MLS, MA
  • Tanja Kalicanin, MLS (ASCP) CM

Additional Information

Learn More

Review additional upcoming CAP evidence-based guidelines by the Center.

Have a Question or Comment?

Send us an email.

Email the Center Right Arrow